Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy
Nils Wellhausen(University of Pennsylvania), Carl H. June(University of Pennsylvania), Philipp C. Rommel(University of Pennsylvania), Sangya Agarwal(Amgen (United States)), Saar Gill(Parker Institute for Cancer Immunotherapy)
Cited by 22
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554